BioAge Labs, Inc. Common Stock (BIOA) is a publicly traded Healthcare sector company. As of May 20, 2026, BIOA trades at $16.26 with a market cap of $681.90M and a P/E ratio of -6.84. BIOA moved -0.61% today. Year to date, BIOA is +27.59%; over the trailing twelve months it is +315.48%. Its 52-week range spans $2.88 to $26.62. Analyst consensus is buy with an average price target of $47.83. Rallies surfaces BIOA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cell Therapy Market to Top $20 Billion by 2030 as BioAge Labs Advances Anti-Aging Research: Global cell therapy market valued at $4.7 billion in 2023 is projected to exceed $20 billion by 2030, driven by stem cells, regenerative biologics and senolytic treatments. BioAge Labs is among leading biotech firms exploring cell-based approaches targeting anti-aging and neurodegenerative diseases.
| Metric | Value |
|---|---|
| Price | $16.26 |
| Market Cap | $681.90M |
| P/E Ratio | -6.84 |
| EPS | $-2.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.62 |
| 52-Week Low | $2.88 |
| Volume | 147.40K |
| Avg Volume | 0 |
| Revenue (TTM) | $10.32M |
| Net Income | $-89.93M |
| Gross Margin | 0.00% |
7 analysts cover BIOA: 0 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $47.83.